Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to ...

MELBOURNE, Australia and INDIANAPOLIS, /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today ...

Liv Hospital integrates PET/CT diagnostics, radionuclide therapies and a multidisciplinary council to create individualized treatment plans for complex cancer and cardiac cases.

The company reported progress on a key China trial and US regulatory resubmissions for two diagnostic imaging agents.

The move suggests that shrinking margins, leadership turnover, and a shifting product mix are quietly reshaping the Lantheus ...

An update from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) is now available. Clarity Pharmaceuticals announced that data from its Phase II Co-PSMA ...

Telix Pharmaceuticals Limited (NASDAQ:TLX) is among the best NASDAQ stocks under $10 to buy. On December 15, RBC Capital assumed coverage on Telix Pharmaceuticals Limited (NASDAQ:TLX) with a Sector ...

Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. The agreement covers PNT2002, a ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation ...

Prostate cancer is highly treatable when detected early, as it carries a favourable prognosis. Therefore, awareness among ...

Learn more about whether Lantheus Holdings, Inc. or Omnicell, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.